Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bionetix Therapeutics

Request full access

A developer of anticancer drugs designed for cancer treatment

Suwon, South KoreaFounded 2017Biotech & Life Sciences

About Bionetix Therapeutics

Bionetix Therapeutics, an entity based in Suwon, South Korea, operates within the biotechnology sector, focusing on the development of novel small molecule drugs. Founded in February 2017, the company directs its research and development efforts toward oncology and ophthalmology. The Chief Executive Officer is Doo-young Jung.

The company's business model centers on advancing its pipeline of drug candidates through clinical trials to address unmet medical needs. Bionetix in-licenses promising compounds from research institutions and progresses them through the development stages. A key collaboration was established in 2017 with Southern Research, a U.S.-based nonprofit research organization, to co-develop a new anti-cancer drug. This agreement provides Bionetix with the option to acquire exclusive global commercialization rights for the resulting inhibitors.

The therapeutic pipeline includes two primary candidates. The first, NTX-301, is a DNA methyltransferase (DNMT) inhibitor intended for the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). This epigenetic approach works by restoring the expression of specific genes to induce the differentiation of cancer cells. Bionetix in-licensed NTX-301 from Southern Research in 2017. The second lead candidate, NTX-101, is being developed for glaucoma. It functions by inhibiting an enzyme to normalize steroid metabolism in ocular tissues, aiming to control intraocular pressure and protect ocular tissue. The company is also developing other therapeutic candidates for oncology.

To finance its operations, Bionetix has successfully raised capital from institutional investors. A notable Series B funding round in January 2020 secured ₩10.8 billion (US$9.33 million), bringing its total funding at the time to ₩14.7 billion. The funds were allocated to advance NTX-301 into a Phase I clinical trial in the U.S. and to further the research and development of NTX-101. Investors in this round included Partners Investment, Stic Ventures, and KB Investment, among others.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
67.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Oct 2025 $58M $232M Undisclosed ↗
SERIES BOther financing Jan 2020 $9.3M $37M Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Bionetix Therapeutics website traffic

Latest recorded traffic for Bionetix Therapeutics is 0 monthly website visits, down 100% over the last three months. Bionetix Therapeutics's team declined 28.6% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth-28.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Bionetix Therapeutics in the Suwon ecosystem

Live from Dealroom

The Bionetix Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Mirae Asset Venture Investment
  • K Partners

Series A1 investor entered at this stage

  • Partners Investment

Other known investors1 additional known investor

  • Korea Research Institute Of Chemical Technology
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇰🇷 South Korea66.7%
🇺🇸 United States33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bionetix Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bionetix Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.